Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis.

Abstract

Aim: We aimed to compare the mortality rates related to adverse events (AEs) and discontinuation of treatment due to toxicity as well as all AEs of currently used regimens of second-line treatment strategies for advanced or metastatic urothelial carcinoma of the bladder. Methods: The MEDLINE and EMBASE databases were searched for articles according to the PRISMA extension statement for network meta-analysis. Results: Five trials comprising 2205 patients met our eligibility criteria. It is highly likely that immunotherapy, as single regimen, has the lowest rates of motor and sensory neuropathies, constipation, abdominal pain, alopecia, decreased appetite, vomiting and febrile neutropenia. Immunotherapy, in combination regimen, has the lowest rates of anemia and fatigue. Conclusion: Immunotherapy, especially as single regimen, demonstrated the highest favorable tolerability to most AEs.

• Authors: Ekaterina Laukhtina, Keiichiro Mori, Hadi Mostafaei, Axel S Merseburger, Peter Nyirady, Marco Moschini, Fahad Quhal, Victor M Schuettfort, Benjamin Pradere, Reza Sari Motlagh, Dmitry Enikeev, Shahrokh F Shariat, European Association Of Urology-Young Academic Urologists Eau-Yau Urothelial Carcinoma Working Group
• Journal: Immunotherapy (Immunotherapy) Vol. 13 Issue 11 Pg. 917-929 (08 2021) ISSN: 1750-7448 [Electronic] England
• PMID: 34078134 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review)

Chemical References

• Antineoplastic Agents, Immunological

Topics

• Antineoplastic Agents, Immunological (therapeutic use)
• Carcinoma, Transitional Cell (drug therapy)
• Humans
• Immunotherapy (adverse effects, methods)
• Network Meta-Analysis
• Salvage Therapy (methods)
• Urinary Bladder Neoplasms (drug therapy)